


Proposes new approach for optimizing for chemical properties collectively using Transfer Learning



Proposes new approach for generating new chemical compounds using





Recurrent Neural Networks

Rise of de novo drug

Methods

19 Further exploration of ML in drua discovery offers enormous potential to reduce the cost and time needed for the development of drugs.


selection

Unrealistic or inferior

Conclusion

molecules with one good

Limitations







Molecules were evaluated based on five

PCA of Molecular Descriptors: Generated Molecules

visualized using PCA

15 <u>Advantages</u>



This cycle of de novo drug design provides scalable generation of molecules with multiobjective optimization.



Optimizing for specific chemical properties is hard

<u>Introduction</u>


7 Molecules are represented using the SMILES string notation




Acetylsalicylic Acid (Aspirin) CC(=0)0c1ccccc1C(=0)0

The network used composed of three stacked LSTM lavers. each of size 1024. regularized with a 0.2 dropout ratio. 21 million trainable


parameters. Sequence length = 75 time steps



Generates molecules and then selects the best ones based on nondominated sorting then train with the newly




10 This process simulates the traditional design-synthesis-test cycle far more rapidly.




Multiobjective de novo drug design with recurrent neural networks and nondominated

sorting. Results




data. 12 77% were valid and 6.295 were duplicates. Filtering left 9.415 unique, novel, and valid

molecules.



After retraining the model with selected molecules, the molecules properties were visualized again.



Iterations